Trial reportScientific reports2025
Bilateral transcutaneous auricular vagus nerve stimulation for the treatment of insomnia in breast cancer.
Trial report in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06006299 (Investigating the Feasibility of Using taVNS to Treat Insomnia in Individuals With Stage I-IV Breast Cancer), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Investigating the Feasibility of Using taVNS to Treat Insomnia in Individuals With Stage I-IV Breast Cancer
Who cites it
1 citing paper in PubMed.
- Transcutaneous vagus nerve stimulation in breast cancer: a neuroimmune model to improve quality of life.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Substantial diagnostic and therapeutic advances have been made in medicine to address breast cancer. There remain unmet needs to translate solutions for addressing insomnia and mental health concerns in breast cancer patients. In this open-label, pilot clinical trial, we evaluated the safety and efficacy of nightly, bilateral, transcutaneous auricular vagus nerve stimulation (taVNS) on insomnia and mental health outcomes in breast cancer patients across a two-week treatment period. Our results demonstrate that noninvasive vagus nerve stimulation can significantly reduce insomnia severity, improve sleep quality, decrease sleep onset latency, and enhance sleep efficiency. Treatment with taVNS also significantly reduced the number of nightly awakenings, cancer-related fatigue, and depression scores while increasing heart rate variability. These observations demonstrate that auricular vagus nerve stimulation holds promise for improving sleep quality and mental health in patients diagnosed with breast cancer. Future investigations aimed at more thoroughly investigating the safety profile and clinical impacts of taVNS on the quality of life in patients with breast cancer are warranted.ClinicalTrials.gov Identifier: NCT06006299 23/08/2023.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.